PFG Investments LLC Grows Position in Pfizer Inc. (NYSE:PFE)

PFG Investments LLC lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 14.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 236,458 shares of the biopharmaceutical company's stock after buying an additional 30,040 shares during the quarter. PFG Investments LLC's holdings in Pfizer were worth $5,992,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Rialto Wealth Management LLC bought a new stake in Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter worth $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer in the 4th quarter valued at $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of Pfizer stock opened at $23.97 on Friday. The stock has a 50 day moving average price of $23.26 and a 200-day moving average price of $24.90. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a market cap of $136.27 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the firm earned $0.82 earnings per share. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.18%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.